Participated · Series A · Jan 2025

Granata Bio is a Boston, MA–based biopharmaceutical company advancing fertility therapeutics and women’s health. Led by CEO Evan Sussman, the company’s pipeline includes a range of fertility therapies developed through collaborations spanning multiple drug classes. Granata Bio is the parent company of Oviva Therapeutics, Inc., a wholly owned subsidiary developing therapeutics to preserve ovarian function and extend female health span. The company received an investment from Gedeon Richter; the amount of the deal was not disclosed. Granata Bio said it will use the funds to expand operations and its R&D efforts. No operating metrics or past financing details were provided in the article. Granata Bio is a US-based biopharma company focused on women's health and reinvigorating the $3.6B global infertility medication market. Its pipeline includes collaborations spanning multiple IVF product classes. The company aims to identify and develop new therapeutic solutions to improve access for fertility patients. With the new funding, Granata plans to progress its existing pipeline and explore additional innovative assets in reproductive health. Granata emphasizes strengthening its leadership position within the reproductive health space and growing solutions for patients. Granata was founded in 2018. Granata Bio is a biopharma company focused on women’s health and the infertility medication market, led by CEO Evan Sussman. The company has assembled a portfolio of four medications that range from commercialized products to early-stage developments. Granata intends to use the new funding to progress its existing pipeline, evaluate new targets, and expand its team. The company raised $14M in a Series A to support those plans. Granata is based in Boston, MA. No revenue or user metrics were disclosed in the article.

Participated · Series A · Jul 2019

DotLab is a personalized medicine company developing DotEndo, a non-invasive diagnostic test intended to detect endometriosis without requiring laparoscopic procedures. The test is physician-ordered through a lab and is explicitly not a genetic test. DotLab completed a Yale University-led validation study for DotEndo and positions the product as a better, cheaper, less painful alternative to current diagnostics. The company raised $10 million in Series A funding to bring the test to market. Investors in the round include CooperSurgical, Tiger Global Management, Luxor Capital Group and law firm Wilson Sonsini Goodrich & Rosati. Next steps for DotLab are to get the test into the hands of physicians so they recommend DotEndo to patients exhibiting symptoms.